Share Name Share Symbol Market Type Share ISIN Share Description
Abzena LSE:ABZA London Ordinary Share GB00BN65QN46 ORD GBP0.002
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +25.25p +70.63% 61.00p 60.00p 62.00p 64.00p 37.50p 37.50p 3,081,519.00 13:44:49
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 9.9 -10.7 -9.0 - 83.60

Abzena Share Discussion Threads

Showing 26 to 44 of 50 messages
Chat Pages: 2  1
DateSubjectAuthorDiscuss
20/1/2017
13:12
Hopefully get picked up by usual culprits next week that should help drive this further IMO, albeit only back to its IPO pricing at least IMO! gla
qs99
20/1/2017
11:56
Yup looks like decent potential here, hopefully this year will see more such deals which is what it is all about IMO. Gla and DYOR, just the beginning IMO
qs99
20/1/2017
10:41
The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
mr hat
20/1/2017
10:25
This was 80p in May!!
gimmetheloot
20/1/2017
10:24
1.3 billion market cap potential within the short term or 12-18 months!! 80 million market cap 15 bagged from her buy and hold that's it!!
gimmetheloot
20/1/2017
10:14
Over 300 million
gimmetheloot
20/1/2017
10:13
The value of the agreement to Abzena has the potential to reach over $300 million, comprising licence fees and milestone payments. In addition, Abzena would also receive royalties on sales of approved products that incorporate the ThioBridge(TM) technology developed by its partner. Dr John Burt, CEO of Abzena, commented: "Abzena and the US biopharmaceutical company has enjoyed an ongoing collaborative research programme to evaluate ThioBridge(TM) up until now. The collaboration has allowed both parties to build a strong working relationship and to demonstrate the value of the ThioBridge(TM) technology in creating novel ADCs. "Signing this extensive licence agreement for ThioBridge(TM) is further validation of our proprietary ADC technology and expertise. We look forward to continuing to work together with our partner for the development of novel ThioBridge(TM)
gimmetheloot
20/1/2017
08:43
yup, prefer this thread, couldn't get the charts to work on mine so ignore that one, apologies. Well done all that are on board! Brokers have 93-£1 target price or intrinsic value price DYOR but IMO the outlook statement from them suggest more to come following further progression on licencing deals etc etc. Very tightly held, but positive news will see this further. GLA and am holding on...
qs99
20/1/2017
08:33
when did you buy in keya ?
arab3
20/1/2017
08:30
Well jog on then.......
keya5000
20/1/2017
07:41
On initial read of rns sounds positive $300million potential income..but then looked at share price last 12 months and fact this deal at lower value was announced 10 months ago and realised it's a classic loss making aim jam tomorrow story
22richyrich
22/12/2016
07:54
License agreement, a step forward?
escapetohome
24/10/2016
18:43
These new appointments need to get cracking and buy some shares.
escapetohome
30/9/2016
09:27
Abzena CEO John Burt will be presenting at the Biotech Capital Conference in London on the 4th October. For further details and to register to attend, please click here: http://tinyurl.com/h55rtx8
aim_trader
26/7/2016
15:02
new video at Proactive Investors is here: http://tinyurl.com/z5fjqs4
sophiegb
11/5/2016
12:30
Someone must be in agreement with that "small' Buy.
5oletrader
11/3/2016
08:45
Video interview with Julian Smith http://tinyurl.com/jaos6uo Julian Smith, chief financial officer at drug developer and pharma services group Abzena (LON:ABZA), tells Proactive Investors the integration of two US companies acquired last year - PacificGMP and TCRS - is "progressing well". Smith explains Abzena's integrated offering will help the company grow as customers are responding well. He adds the licence agreement for ThioBridge is a "fantastic result for the group."
proactivest
05/2/2016
18:39
Woodfords stake now 23%
my retirement fund
02/2/2016
12:28
Julian Smith, CFO, will be presenting to investors on the evening of the 18th February at the Proactive One2One biotech forum at the Chesterfield Hotel in Mayfair. To register to attend this event, please click here: http://tinyurl.com/z42o5am
aim_trader
Chat Pages: 2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170120 14:01:50